User login
Key clinical point: Ramucirumab offers clinically significant efficacy with no new safety signals after non-sorafenib systemic therapies in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥400 ng/mL.
Major finding: Median overall and progression-free survival were 8.7 (95% CI 4.6-12.2) months and 1.7 (95% CI 1.5-4.1) months, respectively. The objective response rate was 10.6% (95% CI 1.8%-19.5%), and the disease control rate was 46.8% (95% CI 32.5%-61.1%). The grade ≥3 adverse event (AE) rate was 57%, with hypertension (11%) being the most frequent AE.
Study details: This open-label, non-comparative cohort of the REACH-2 study included 47 patients with advanced HCC and baseline AFP ≥400 ng/mL who had received non-sorafenib-based systemic therapies.
Disclosures: This study was funded by Eli Lilly and Company, U.S. Some authors declared serving as consultants or advisors for or receiving research funding or honoraria from various sources, including Eli Lilly. Four authors declared being employees of Eli Lilly.
Source: Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: An expansion cohort of REACH-2. Oncologist. 2022 (Oct 3). Doi: 10.1093/oncolo/oyac183
Key clinical point: Ramucirumab offers clinically significant efficacy with no new safety signals after non-sorafenib systemic therapies in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥400 ng/mL.
Major finding: Median overall and progression-free survival were 8.7 (95% CI 4.6-12.2) months and 1.7 (95% CI 1.5-4.1) months, respectively. The objective response rate was 10.6% (95% CI 1.8%-19.5%), and the disease control rate was 46.8% (95% CI 32.5%-61.1%). The grade ≥3 adverse event (AE) rate was 57%, with hypertension (11%) being the most frequent AE.
Study details: This open-label, non-comparative cohort of the REACH-2 study included 47 patients with advanced HCC and baseline AFP ≥400 ng/mL who had received non-sorafenib-based systemic therapies.
Disclosures: This study was funded by Eli Lilly and Company, U.S. Some authors declared serving as consultants or advisors for or receiving research funding or honoraria from various sources, including Eli Lilly. Four authors declared being employees of Eli Lilly.
Source: Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: An expansion cohort of REACH-2. Oncologist. 2022 (Oct 3). Doi: 10.1093/oncolo/oyac183
Key clinical point: Ramucirumab offers clinically significant efficacy with no new safety signals after non-sorafenib systemic therapies in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥400 ng/mL.
Major finding: Median overall and progression-free survival were 8.7 (95% CI 4.6-12.2) months and 1.7 (95% CI 1.5-4.1) months, respectively. The objective response rate was 10.6% (95% CI 1.8%-19.5%), and the disease control rate was 46.8% (95% CI 32.5%-61.1%). The grade ≥3 adverse event (AE) rate was 57%, with hypertension (11%) being the most frequent AE.
Study details: This open-label, non-comparative cohort of the REACH-2 study included 47 patients with advanced HCC and baseline AFP ≥400 ng/mL who had received non-sorafenib-based systemic therapies.
Disclosures: This study was funded by Eli Lilly and Company, U.S. Some authors declared serving as consultants or advisors for or receiving research funding or honoraria from various sources, including Eli Lilly. Four authors declared being employees of Eli Lilly.
Source: Finn RS et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: An expansion cohort of REACH-2. Oncologist. 2022 (Oct 3). Doi: 10.1093/oncolo/oyac183